Main features of ischemic stroke in patients with acute immune-mediated thrombotic thrombocytopenic purpura.

BACKGROUND

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a microangiopathy often characterized by acute neurological involvement including ischemic stroke (IS). The characteristics of IS in iTTP remain largely unknown.

AIMS

To evaluate the epidemiology, neuroimaging patterns and risk factors of IS in iTTP patients.

METHODS

We performed a cross-sectional study of patients enrolled in the Milan TTP Registry presenting with neurological signs/symptoms and underwent neuroimaging evaluation during their first acute iTTP episode.

RESULTS

Seventy-eight patients were enrolled, the majority of patients were female (72 %), with a median age of 46 years. Computed tomography (CT) was performed in all patients, and magnetic resonance (MRI) was performed in 38 % of patients. IS was confirmed in 18 out of 78 patients (23 %), most of whom (70 %) showed a non-lacunar pattern with multifocal involvement. In the subgroup of patients who had MRI (n = 30), IS was identified in 12 patients (40 %) and of them 6 (50 %) had a false negative result with CT scan. Patients with IS were slightly older than those without, whereas the prevalence of cardiovascular risk factors and iTTP-related parameters were comparable between the two groups.

CONCLUSION

23 % of patients presenting with neurological manifestations at their first acute TTP episode, showed brain IS. As expected, MRI showed higher sensitivity in detecting ischemic lesions underscoring its usefulness over CT in this setting. An unexpected prevalence of non-lacunar and multifocal stroke patterns warrants further investigation. Cardiovascular risk factors and iTTP-related clinical and laboratory parameters were similarly distributed in patients with and without IS.

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: P. Agosti, A. Artoni, and B. Ferrari received honoraria for participating as a speaker at educational meetings organized by Sanofi; I. Mancini received honoraria for participating as a speaker at educational meetings organized by Werfen and Sanofi; F. Peyvandi has received honoraria for participating as a speaker in education meetings organized by Sanofi, Spark and Takeda and she is member of scientific advisory boards of CSL Behring, Biomarin, Roche, Sanofi, Sobi. The other authors do not have any conflict of interests to disclose.